ALK and neuroblastoma: Studies in neuroblastoma have revealed that R1275Q and wild-type ALK-amplified cell lines are highly sensitive to crizotinib [44, 47, 48], whereas cell lines harboring the ALK F1174L mutation are less so, but still more responsive to treatment than non-amplified, wild-type ALK cell lines [44, 47].